Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

To see complete record on, please visit this link

Id: NCT03344419

Organisation Name: New York State Psychiatric Institute

Overal Status: Recruiting

Start Date: October 1, 2017

Last Update: June 1, 2022

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cocaine use disorders.

  • Cocaine Use Disorder

Total execution time in seconds: 0.28158497810364